Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Vaccine Conjugates Companies

Vaccine conjugates companies specialize in the development and production of conjugate vaccines. Conjugate vaccines are created by combining a bacterial or viral antigen with a carrier protein, enhancing the immune system's response, particularly in the case of certain bacteria that have polysaccharide capsules. These vaccines are crucial in preventing infections caused by bacteria like Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis.

Vaccine Conjugates Market

 


Latest Vaccine Conjugates Companies Updates:


Pfizer Inc. (US): Received FDA approval for its Prevnar 20® pneumococcal conjugate vaccine for adults in October 2023, expanding its market reach and potential revenue stream.


Merck & Co., Inc. (US): Partnered with PATH (US) in September 2023 to develop and introduce a new MenB vaccine conjugate for low- and middle-income countries, addressing global health disparities.


GlaxoSmithKline plc (UK): Highlighted its ongoing development of a malaria vaccine conjugate in its recent investor presentation, showcasing its commitment to innovative vaccine solutions.


Bharat Biotech International Limited (India): Announced successful Phase 3 clinical trials for its Typhoid Conjugate Vaccine in July 2023, paving the way for potential market entry and wider access to this important vaccine.


Novavax, Inc. (US): Presented promising preclinical data for its respiratory syncytial virus (RSV) F protein conjugate vaccine candidate in September 2023, adding to the pipeline of potential new conjugate vaccines.


List of Vaccine Conjugates Key companies in the market:



  • Bharat Biotech (India)

  • GlaxoSmithKline Plc (UK)

  • Serum Institute of India

  • Sanofi Pasteur (France)

  • Merck and Company (US)

  • CSL Limited (Australia)

  • Pfizer Inc. (US)

  • Novartis AG (Switzerland)

  • Neuron Biotech (the US) 

  • Biological E (India)


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.